Skip to main content
. Author manuscript; available in PMC: 2014 Jan 27.
Published in final edited form as: Cancer Res. 2011 Jul 12;71(14):4846–4856. doi: 10.1158/0008-5472.CAN-11-0414

Figure 4.

Figure 4

The effect of GCNT2 on distal metastasis in vivo. A and C, quantification of metastasis in vivo. A, 2 populations of EpRas cells with the vector (LacZ) or the GCNT2 gene were used in 10 mice, respectively. C, 4T1 cells with nontarget control and GCNT2 shRNA1 and shRNA5 were used in 5 and 8 mice, respectively. Representative H&E staining pictures of lung sections from mice injected with genetically modified EpRas or 4T1-derived cells are shown as low panels (magnification, 100× and 200×). B, representative figures of the tumor burdens for EpRas cells with vector control and GCNT2 expression. No significant difference was observed (P = 0.778954). D, representative figures of the tumor burdens for 4T1 cells with nontarget control, shRNA clone1, and shRNA clone5. Significant decrease in tumor weight was observed in GCNT2 knockdown clones.